Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Multiplicom Launches Two New Diagnostic Kits

Published: Tuesday, June 03, 2014
Last Updated: Tuesday, June 03, 2014
Bookmark and Share
Company aims for strong growth in the rapidly expanding molecular diagnostic market.

Multiplicom NV has announced that it has achieved ISO 13485 accreditation, and is launching two new CE/IVD labeled DNA mutation detection kits for Cystic Fibrosis (CF) and Familial Mediterranean Fever (FMF), genetics diseases with a high carrier rate.

Dr Dirk Pollet, CEO of Multiplicom, said: “Having ISO 13485 accreditation establishes Multiplicom as a reliable supplier of diagnostic kits to clinical labs as well as to the major diagnostic companies worldwide. All Multiplicom MASTR products have a uniform protocol, require only standard equipment and are compatible with MPS equipment from Roche, Illumina and Thermo Fisher. The introduction of the new kits establishes Multiplicom as a European leader in the implementation of MPS in the routine clinical labs, enabling personalized medicine.”

Multiplicom was recently awarded ISO 13485:2003 and ISO 13485:2012 certification for “Design, development, manufacturing and distribution of in vitro molecular diagnostic test kits used for the identification of genomic and somatic variants.”

This week, at the European Society for Human Genetics in Milan, Multiplicom has announced the launch of two new CE/IVD labeled MASTR kits, for the comprehensive detection of mutations associated with CF in June and FMF in July. With these new CE/IVD labeled kits Multiplicom aims to take a significant market share in the screening markets for both diseases.

Multiplicom is operating in an area of rapid growth. The European MPS diagnostic market is expected to grow from €20M in 2012 to >€2,000M in 2018 (CAGR% >100%) within a worldwide market of >€6,000M in 2018.

Based on its success in Europe, with expected sales in 2014 of > €6M (CAGR%>100%), the ISO 13485 accreditation and the launch of new products for both genomic and somatic mutations, Multiplicom is now in pole position for additional growth in other major territories.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Multiplicom Appoints Board Chairman
Appointment of Dr Ian Gilham as Chairman of the Board of Directors.
Thursday, June 27, 2013
Multiplicom’s BRCA MASTR™ Dx Test Accredited with CE/IVD Mark
BRCA MASTR Dx will be shipped throughout Europe from September 2012.
Wednesday, June 20, 2012
Multiplicom Receives €200,000 Grant for Novel Non-Invasive Pre-Natal Test
IWT grant to support development of early aneuploidy detection during pregnancy.
Thursday, June 07, 2012
Scientific News
Gene Editing Could Enable Pig-To-Human Organ Transplant
The largest number of simultaneous gene edits ever accomplished in the genome could help bridge the gap between organ transplant scarcity and the countless patients who need them.
Antioxidants Cause Malignant Melanoma to Metastasize Faster
Fresh research at Sahlgrenska Academy has found that antioxidants can double the rate of melanoma metastasis in mice.
UC San Diego Team Up with Illumina to Speed-Read Your Microbiome
Data analysis app accelerates studies aimed at using microbes to predict, diagnose and treat human diseases.
Paving the Way for Diamonds to Trace Early Cancers
Researchers from the University of Sydney reveal how nanoscale 'diamonds' can light up early-stage cancers in MRI scans.
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos